AbbVie, Inc. (ABBV)

In April 2026, AbbVie's shares increased to $214.14, reaching a 4-week high, but also saw decreases to 35-week and 33-week lows. On April 29, 2026, AbbVie reported strong first-quarter 2026 financial results, exceeding expectations and leading to a more than 3% intraday rise in shares. In May 2026, AbbVie announced a quarterly dividend of $1.73 per share. On May 9, 2026, AbbVie reported record 2025 results at its annual meeting, with total net revenues of $61.2 billion and adjusted EPS of $10.54.

AbbVie's business generally does not have significant seasonality, but product revenues can be affected by end-customer and retail buying patterns, fluctuations in wholesaler inventory levels, and other factors. The healthcare sector, in which AbbVie operates, has historically shown a period of seasonal strength from April 25 to December 4.

AbbVie Inc. is a research-based biopharmaceutical company that focuses on discovering and delivering innovative medicines across several key therapeutic areas, including immunology, oncology, neuroscience, eye care, and medical aesthetics. Key immunology products include Humira, Skyrizi, and Rinvoq, which treat autoimmune and inflammatory diseases. Oncology treatments include Imbruvica and Venclexta for blood cancers, with newer drugs like Elahere, Epkinly, and Emrelis. Neuroscience products include Botox Therapeutic, Vraylar for schizophrenia and bipolar disorder, Duopa/Duodopa for Parkinson's disease, and migraine treatments Ubrelvy and Qulipta. The Allergan Aesthetics portfolio includes Botox Cosmetic and the Juvederm Collection. Other key products include Mavyret for Hepatitis C, Creon for pancreatic enzyme therapy, Linzess/Constella for irritable bowel syndrome, and various eye care products.

AbbVie has a significant global presence, marketing its products in over 170 countries. The company operates in 5 world regions and more than 70 countries. Its corporate headquarters are in North Chicago, Illinois, USA. Within the United States, AbbVie has manufacturing facilities in Illinois, Massachusetts, and Michigan, and R&D facilities in Illinois, California, Massachusetts, and Sunnyvale, CA. Internationally, manufacturing facilities are located in Puerto Rico, Italy, Ireland, Germany, and Singapore, with principal R&D facilities in Germany and Japan. The United States represents the largest portion of AbbVie's total revenue, accounting for 76.38% in fiscal year 2024 and 95.17% in fiscal year 2025.

AbbVie's brand reputation has been influenced by its strong financial performance and strategic pipeline development, despite challenges. Strong first-quarter 2026 results and growth beyond Humira have positively impacted sentiment. The completion of an early safety study for ABBV-142 also improved investor confidence. However, the patent expiration of Humira and subsequent competition from biosimilars have led to a significant decline in Humira sales, impacting the company's revenue. Additionally, the aesthetics segment has experienced soft sales due to macro challenges and economic headwinds.

AbbVie's stock is primarily held by large financial institutions, which collectively hold approximately 84.61% of the shares. The Vanguard Group is the largest institutional shareholder, holding approximately 10.22% of the company's stock. Other significant institutional owners include BlackRock Inc., State Street Corp, Geode Capital, JP Morgan Asset Management, and Charles Schwab Investment Management. Public companies and individual investors collectively own approximately 51.66% of AbbVie's stock, while insiders hold a small percentage, around 0.06%.